{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-015945","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.778425+00:00","generated_at":"2026-05-14T21:16:53.082212+00:00","sec_items":["1.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmuCell settles Norbrook dispute, to receive $2M payment","bullets":["ImmuCell and Norbrook entered a Settlement Deed on May 8, 2026 resolving all claims from a 2019 Development and Supply Agreement.","Norbrook will pay ImmuCell $2,000,000 under the settlement.","The underlying agreement expired on March 31, 2026.","Settlement deed governed by Northern Ireland law; no admission of liability or wrongdoing.","Confidentiality undertakings included in the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-015945","json":"https://secwatch.observer/filing/0001437749-26-015945.json","markdown":"https://secwatch.observer/filing/0001437749-26-015945.md","text":"https://secwatch.observer/filing/0001437749-26-015945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/iccc20260508_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:16:53.082212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bb2969d5558b43d2fc4726f4f0d2309d130c4ca","claim":"IMMUCELL CORP /DE/ entered into Settlement Deed with Norbrook Laboratories Limited valued at $2,000,000 (effective 2026-05-08).","evidence_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001437749-26-014906","ticker":"SGRP","company_name":"SPAR Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-014906","json":"https://secwatch.observer/filing/0001437749-26-014906.json","markdown":"https://secwatch.observer/filing/0001437749-26-014906.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/sgrp20260505_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm"}},{"accession":"0001628280-26-027280","ticker":"OPY","company_name":"OPPENHEIMER HOLDINGS INC","filed_at":"2026-04-27T23:59:59+00:00","headline":"Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-027280","json":"https://secwatch.observer/filing/0001628280-26-027280.json","markdown":"https://secwatch.observer/filing/0001628280-26-027280.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/opy-20260424.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"On April 24, 2026, Oppenheimer & Co., Inc. (“Oppenheimer”), the principal operating subsidiary of Oppenheimer Holdings Inc. (the “Company”), reached an agreement to settle the previously disclosed litigation styled Liberty Capital Group, Individually and on Behalf of All Others Similarly Situated v. Oppenheimer Holdings Inc., Oppenheimer & Co. Inc., and Oppenheimer Asset Management Inc. , No. 1:25-cv04822-JSR which was filed in the United States District Court for the Southern District of New York in June of 2025 (the “ District Court”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm"}},{"accession":"0001805651-26-000038","ticker":"MKTW","company_name":"MARKETWISE, INC.","filed_at":"2026-04-24T23:59:59+00:00","headline":"MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001805651-26-000038","json":"https://secwatch.observer/filing/0001805651-26-000038.json","markdown":"https://secwatch.observer/filing/0001805651-26-000038.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/mktw-20260421.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm"}},{"accession":"0001171843-26-002591","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-04-21T23:59:59+00:00","headline":"Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment","event_type":"litigation","sec_items":["1.01","5.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002591","json":"https://secwatch.observer/filing/0001171843-26-002591.json","markdown":"https://secwatch.observer/filing/0001171843-26-002591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/f8k_042026.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"On April 10, 2026, Allied Gaming & Entertainment Inc. (the “Company”) and Yangyang Li, its Chief Executive Officer and Chairman, in his personal capacity (“Mr. Li”, and together with the Company, the “Allied Parties”) entered into a binding Term Sheet for Global Resolution (the “Term Sheet”) with Knighted Pastures, LLC (“Knighted”) and Roy Choi, in his personal capacity (“Mr. Choi”, and together with Knighted, the “Knighted Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm"}},{"accession":"0001193125-26-157030","ticker":"MCHX","company_name":"MARCHEX INC","filed_at":"2026-04-15T23:59:59+00:00","headline":"Marchex settles civil lawsuit for $2M, payments spread over 13 months","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-157030","json":"https://secwatch.observer/filing/0001193125-26-157030.json","markdown":"https://secwatch.observer/filing/0001193125-26-157030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/mchx-20260414.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm"}},{"accession":"0001628280-26-024527","ticker":"CPT","company_name":"CAMDEN PROPERTY TRUST","filed_at":"2026-04-09T23:59:59+00:00","headline":"Camden Property Trust settles RealPage antitrust class action for $53M","event_type":"litigation","sec_items":["1.01","7.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-024527","json":"https://secwatch.observer/filing/0001628280-26-024527.json","markdown":"https://secwatch.observer/filing/0001628280-26-024527.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/0001628280-26-024527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/cpt-20260407.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"On April 7, 2026, Camden Property Trust, on behalf of itself and related entities (collectively, the “Company”) entered into a binding term sheet for a settlement with the named plaintiffs in the Class Action Litigation, individually and on behalf of the class members (together, the “Plaintiffs”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/0001628280-26-024527-index.htm"}},{"accession":"0001829126-26-003120","ticker":"SLND","company_name":"Southland Holdings, Inc.","filed_at":"2026-04-02T23:59:59+00:00","headline":"Southland subsidiary settles WA convention center lawsuit; sureties to pay additional $26.5M","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-003120","json":"https://secwatch.observer/filing/0001829126-26-003120.json","markdown":"https://secwatch.observer/filing/0001829126-26-003120.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/0001829126-26-003120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/southland_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"On March 27, 2026, American Bridge Company (“American Bridge”), a wholly owned subsidiary of Southland Holdings, Inc. (the “Company”), entered into a Settlement Agreement and Release of Claims (the “Settlement Agreement”) with Clark/Lewis, a Joint Venture (“Clark/Lewis”), certain sureties of American Bridge (the “Sureties”), the Washington State Convention Center (“WSCC”), and American Bridge’s litigation counsel.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/0001829126-26-003120-index.htm"}},{"accession":"0001140361-26-010656","ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2026-03-23T23:59:59+00:00","headline":"Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-010656","json":"https://secwatch.observer/filing/0001140361-26-010656.json","markdown":"https://secwatch.observer/filing/0001140361-26-010656.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/ef20068452_8ka.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","comparable_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}